Christopher J. Sweeney

Research interests

Publications

• Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

  Nature Medicine · 2022 · 10.1038/s41591-021-01600-6

• Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00336-3

• Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium

  Journal of Clinical Oncology · 2021 · 10.1200/jco.20.03296

• Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00580-8

• Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

  European Urology · 2020 · https://doi.org/10.1016/j.eururo.2020.01.012

• Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1903835

• Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(18)30904-5

• Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis

  European Urology · 2019 · 10.1016/j.eururo.2019.02.003

• Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2017.75.3780

• Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

  European Urology · 2018 · https://doi.org/10.1016/j.eururo.2018.02.001

• Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2017.75.3657

• Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer

  European Urology · 2018 · 10.1016/j.eururo.2018.11.045

• Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

  European Urology · 2017 · https://doi.org/10.1016/j.eururo.2017.06.002

• Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2017.73.9987

• Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1503747

• Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00489-1

• Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

  Annals of Oncology · 2015 · https://doi.org/10.1093/annonc/mdv257

• Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates

  Journal of Clinical Oncology · 2014 · 10.1200/jco.2013.52.4785

• Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation

  Proceedings of the National Academy of Sciences · 2014 · 10.1073/pnas.1324151111

• Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

  Journal of Clinical Oncology · 2012 · 10.1200/jco.2012.45.0494

• Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer

  JAMA · 2010 · 10.1001/jama.2010.1720

• An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells

  Blood · 2007 · https://doi.org/10.1182/blood-2007-05-090621

• Redefining the Target: Chemotherapeutics as Antiangiogenics

  Journal of Clinical Oncology · 2001 · 10.1200/jco.2001.19.4.1195

• Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594

  Cancer · 2001 · 10.1002/1097-0142(20011115)92:10<2639::aid-cncr1617>3.0.co;2-8

• The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.

  PubMed · 2001

Current projects

No projects listed.